Skip to main content
Peter MacCallum Cancer Centre
  • Donate
  • Location
  • Search
  • English
  • Easy English
  • العَرَبِيَّة Arabic
  • 中文 Chinese
  • Eλληνικά Greek
  • हिन्दी Hindi
  • Italiano Italian
  • Tagalog Tagalog
  • Türkçe Turkish
  • Tiếng Việt Vietnamese
  • About
  • Profiles
  • Careers
  • Education
  • News
  • Events
  • Get involved
  • Contact
  • Cancer types
    • Breast
    • Upper Gastrointestinal
    • Lower Gastrointestinal
    • Genitourinary Oncology
    • Gynae-oncology
    • Clinical Haematology
    • Head & neck
    • Lung
    • Melanoma & Skin
    • Neuro-oncology
    • Paediatric
    • Sarcoma
    • Cancer of unknown primary
  • Our services
    • Diagnosis & investigations
    • Treatment
    • Support services
    • Cancer information & resources
  • Coming to Peter Mac
    • Melbourne
    • Bendigo
    • Box Hill
    • Moorabbin
    • Sunshine
    • Telehealth
  • Research & discovery
    • Clinical research
    • COE in Cellular Immunotherapy
    • Research laboratories
    • Core facilities and services
    • ProsTIC
    • Research cohort studies
    • Research programs
    • Doing research with us
    • Commercialisation, partnerships and industry engagement
    • Publications
    • Education in research
    • Health Services Research
  • Clinical Trial Care
    • Patients and Families
    • Health Professionals
    • Clinical Trial Sponsors
  1. Home
  2. Profiles
  3. Assoc Prof Dominic Wall
Executive Director of Business Ventures

A/Prof Dominic Wall

haematology and pathology

Biography

Associate Professor Dominic Wall is Peter Mac's Executive Director of Business Ventures.

This role provides leadership and management for programs and departments relating to both existing and emerging business ventures, specifically: the current Pathology services and an associated business unit - nexomics - which provides specialised accredited medical oncology testing for clinical research, as well the new national Centre of Excellence in Cellular Immunotherapy which was established in 2019 with an $80 million contribution from the Commonwealth Government.

This program intends to provide new means for Australian patients to access innovative cell based immunotherapy products such as CAR-T cells.

He is also the Chief Scientific Officer of Peter Mac’s majority owned and controlled independent and commercial business Cell Therapies Pty Ltd which provides specialised contract manufacturing and testing of cells for human therapy, predominantly in the field of cellular immunotherapy and gene therapy.

Dominic is the responsible person to provide the executive support for all of these businesses to flourish in a public hospital setting.

Dominic has been directly involved in cell therapy manufacturing since the 1990s and was responsible for manufacturing Australia’s first CAR-T products in 2008. Cell Therapies has Australia’s only TGA licence for manufacturing of both commercial and clinical trial CAR-T products, and Dominic carries final accountability for quality and manufacturing of those products.

He has been also involved in pathology service delivery since his training in London at the University of London School of Pathology at Middlesex & UCH, followed by a PhD at the University of Melbourne and a Founding Fellowship in the Faculty of Science in the Royal College of Pathologists of Australasia.

He was responsible for the expansion and re-establishment of specialised pathology services at Peter Mac in 2001, having fully restructured the services, establishing new on-site services for histology and microbiology and establishing a new 24-hour core laboratory service. His technical expertise is in cell-based therapy, immunology and flow cytometry as well as restructure and corporatisation of internal hospital services.

His research interest is in-vivo cell therapy imaging using PET/SPECT and MRI using novel imaging agents to track the activity and life of these cells in patients. He is the current chair of the Legal & Regulatory Subcommittee of the International Society for Cell Therapy (ANZ) and has been the regional president of his professional society (ISCT) twice. His passion is to bring new technologies into life at Peter Mac,  such as gene modified cells for therapy which are proving to be potent and effective new treatments for cancer, and which can save lives. Bringing these technologies to Australian patients requires new funding models and new partnerships with other hospitals, companies and government.

Related Links

  • Cell Therapies
  • Pathology
  • Haematolgy

Qualifications

BSc (Hons) PhD FFSc (RCPA)

Publications

Books:

Contributing author, Haemostasis Section, in “Laboratory Haematology, an Account of Laboratory Practices”, 1st Edition, Editor I.Chanarin. Churchill Livingstone,1989.

Recent journal articles:

  • Gowans EJ, Roberts S, Jones K, Dinatale I, Latour PA, Chua B, Eriksson EM, Chin R, Li S, Wall DM, Sparrow RL, Moloney J, Loudovaris M, Ffrench R, Prince HM, Hart D, Zeng W, Torresi J, Brown LE, Jackson DC. A Phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. J Hepatol 2010 53(4): 599-607.
  • Trickett AE and Wall D Regulation of cellular therapy in Australia. Pathology 2011 43(6), pp. 627–634
  • Gambell P, Herbert K, Dickinson M, Stokes K, Bressel M, Wall D, Harrison S, Prince HM. Peripheral Blood CD34(+) Cell Enumeration as a Predictor of Apheresis Yield: An Analysis of More Than 1,000 Collections. Biol Blood Marrow Transplant. 2012 [Jan epub]
  • Khot A, Dickinson M, Stokes K, Harrison S, Burbury K, Fleming S, Wall D, Gambell P, Prince HM, Seymour J, Ritchie D. A Risk Adapted Protocol For Delayed Administration Of rhG-CSF Following High Dose Chemotherapy And Autologous Stem Cell Transplantation. Clin Lymphoma, Myeloma & Leukemia 2013 13 (1): 42-7.
  • Ritchie DS, Neeson PJ, Khot A, Peinert S, Tai T, Tainton K, Chen K, Shin M, Wall DM, Hönemann D, Gambell P, Westerman DA, Haurat J, Westewood JA, Scott AM, Kravets L, Dickinson M, Trapani JA, Smyth MJ, Darcy PK, Kershaw MH, Prince HM. Persistence and efficacy of second generation CAR-T cells against the LeY antigen in acute myeloid leukemia. Mol Ther. 2013 Jul 8
  • Herbert KR, Gambell P, Link EK, Mouminoglou A, Stokes K, Wall DM, Harrison SJ, Ritchie DS, Seymour JF, Prince HM. Pegfilgrastim compared to filgrastim for cytokine-alone mobilization of autologous hematopoietic stem and progenitor cells. Bone Marrow Transplant. 2013; 48(3):351-6
  • Tuch BE, Wall DM. Perspectives - Self-regulation of autologous cell therapies. MJA. 2014; 200(4)
  • Tuch BE, Wall DM. Letters  - Self-regulation of autologous cell therapies. MJA. 2014; 201(9)
  • Massimo Dominici, Karen Nichols, Alok Srivastava, Daniel J. Weiss, Paul Eldridge, Natividad Cuende, Robert J. Deans, John E.J. Rasko, Aaron D. Levine, Leigh Turner, Deborah L. Griffin, Lynn O'Donnell, Miguel Forte, Chris Mason, Edwin Wagena, William Janssen, Robert Nordon, DM Wall, Hong-Nerng Ho, Milton A. Ruiz, Steve Wilton, Edwin M. Horwitz, Kurt C. Gunter. Positioning a Scientific Community on Unproven Cellular Therapies: The 2015 International Society for Cellular Therapy Perspective. Cytotherapy 2015; 17(12) 1663-6.

Executive Director of Business Ventures

A/Prof Dominic Wall

haematology and pathology

Clinical Haematology

Clinical Haematology is a unified department formed between Peter Mac and the Royal Melbourne Hospital and is the largest haematology service in the country. We provide a publicly funded, evidence-based care for patients with haematologic disorders from across Melbourne and beyond, within eight...
Read more

Peter MacCallum Cancer Centre

  • Victorian Comprehensive Cancer Centre building
    305 Grattan Street
    Melbourne VIC 3000
    Australia
    Peter MacCallum Cancer Centre
  • (03) 8559 5000 (In an emergency, call 000)
  • (03) 8559 7379 (Main fax)
  • (03) 8559 7371 (Referrals fax)
  • Locations
    • Melbourne
    • Bendigo
    • Box Hill
    • Moorabbin
    • Sunshine
  • About us
    • Get involved
    • Upcoming events
    • Partnerships
    • Patient charter
  • Cancer types
  • Cancer services
    • Diagnosis & investigations
    • Treatments
    • Cancer info & resources
  • Refer your patient
  • Peter MacCallum Cancer Foundation
  • Australian Cancer Survivorship Centre
  • Research & discovery
    • Clinical research & trials
    • Research cohort studies
    • Research labs
  • Careers
  • Education

Our Community

  • Facebook
  • Twitter
  • Instagram
  • YouTube
  • LinkedIn
  • Contact us
Comments & feedback

The Peter MacCallum Cancer Centre acknowledges the traditional owners of the land on which our five sites are located throughout Victoria. We recognise their strength and resilience and pay our respects to their Elders past and present.

Languages
Auslan
Interpreter
Site by Icon Agency
  • Privacy policy
  • Terms & Conditions
  • Intranet